WCLC 2025: Taletrectinib Durability Strengthened as Zidesamtinib Shows Intracranial Activity in ROS1+ NSCLC

Researchers presented longer follow-up for taletrectinib alongside early zidesamtinib data, with any indirect comparisons characterized as preliminary.